Market credibility
Category structure, demand, competition, growth claims, whitespace, and the company's realistic addressable position.
Due diligence
Digital Health Due Diligence
Pressure-test the market story, company evidence, and execution assumptions before capital or strategic commitment.
The decision context
Healthcare startup due diligence must go beyond the data room
Digital health companies operate at the intersection of technology, healthcare delivery, regulation, evidence, and enterprise procurement. Claims that sound credible in isolation can look very different when compared with category peers, buyer behaviour, and the company's actual record of execution.
Galen Growth adds an independent market and ecosystem lens to investment, partnership, and acquisition diligence, focusing the analysis on the risks that can change the decision.
What Galen Growth evaluates
Evidence organised around the decision
Commercial validation
Customer and partnership quality, deployment depth, repeatability, sales-cycle reality, and concentration risk.
Clinical and regulatory evidence
Strength and relevance of evidence, regulatory position, claims, and gaps relative to the intended use.
Execution and strategic risk
Team capability, capital history, dependencies, partner fit, scalability, and the assumptions that require validation.
HealthTech Alpha evidence
Independent evidence against a relevant peer set
HealthTech Alpha enables a target to be compared with ventures operating in the same category, geography, customer environment, and maturity stage. We trace the underlying funding, partnership, clinical, regulatory, and organisational records so findings remain explainable and auditable.
- Custom peer benchmarking
- Partnership and customer validation
- Evidence and regulatory review
- Red-flag and assumption testing
Methodology
From question to defensible action
- Prioritise the thesis
Identify the investment or partnership assumptions that would materially change valuation, fit, or willingness to proceed.
- Build the peer set
Select comparable companies by category, market, business model, customer, and maturity rather than by label alone.
- Test the evidence
Compare claims with observable commercial, clinical, regulatory, organisational, and ecosystem signals.
- Report for decision
Separate confirmed strengths, unresolved questions, material risks, and post-deal priorities.
Related case studies
How Galen Growth has supported these decisions
Macro and micro-environment analysis in RWD & RWE
The Corporate Venture Capital (CVC) arm of a global pharmaceutical company wanted to analyse a specific key APAC market to assess both the macro and micro-environment for Real World Data and Real Word Evidence to inform corporate strategy and prioritise key ventures for further engagement. By utilising Galen Growth's proven PlayBook methodology, we enabled our client to fully understand the RWD and RWE innovation environment and readiness to enable the identification and prioritisation of Digital Health ventures with the right capabilities and achievements. Further prioritisation driven by Deep Dive analysis of select ventures, to map their operating model, leading to direct engagement with their leadership team. The examination covered 1 key therapeutic area in 1 key APAC country. We screened 15 ventures and, in collaboration with our client, shortlisted 7.
Shortlisting personal health ventures in key therapeutic areas
A global leading medical device company sought to understand the personal health Digital Health landscape for two priority therapeutic areas in key global ecosystems to identify and evaluate relevant ventures
Strategic Digital Health decision making and acceleration across Asia Pac
This global Insurer looked to accelerate its Digital Health footprint in Asia, prioritise markets for innovation, and scout for HealthTech ventures that met specific Therapeutic and Category objectives
Related research
Evidence behind the market
Sectors
Designed for healthcare decisions
- Venture capital
- Private equity
- Corporate development
- Biopharma
- Medical device
- Health systems
FAQ
Common questions
What does digital health due diligence cover?
It can cover market attractiveness, competitive position, commercial traction, partnerships, clinical evidence, regulation, organisational capability, and strategic fit.
Is this financial or legal due diligence?
No. Galen Growth complements financial, legal, technical, and clinical specialists with independent digital health market, ecosystem, and company intelligence.
Can due diligence support a partnership decision?
Yes. The scope can focus on partner suitability, evidence quality, implementation readiness, strategic fit, and risks that may affect deployment or scale.
Related capabilities
Explore other decision areas
Your decision context
Bring us the question that needs a defensible answer.
We will help define the evidence, scope, and practical route from analysis to action.